Daniel Mendez
Family Medicine · Palm Springs, CANPI 1841649712
Payments from drug & device makers
Across 90 payments — averaging $44.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$587
- AstraZeneca$541
- Bayer$324
- Johnson & Johnson$320
- AbbVie$249
- GSK$227
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,029100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $587 |
| AstraZeneca | 8 | $541 |
| Bayer | 7 | $324 |
| Johnson & Johnson(2 entities) | 4 | $320 |
| AbbVie | 2 | $249 |
| GSK | 11 | $227 |
| Gilead | 4 | $186 |
| Astellas Pharma US Inc | 3 | $178 |
| Merck | 4 | $171 |
| Boehringer Ingelheim | 7 | $164 |
| Si-bone, Inc. | 1 | $134 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $124 |
| Sunovion Pharmaceuticals Inc. | 1 | $123 |
| Pfizer | 6 | $119 |
| Novo Nordisk | 6 | $103 |
| Axsome Therapeutics, Inc. | 1 | $89 |
| Sanofi Pasteur Inc. | 1 | $83 |
| Beone Medicines USA, Inc. | 2 | $41 |
| Viiv Healthcare Company | 1 | $31 |
| Lilly USA, LLC | 1 | $30 |
| Averitas Pharma Inc. | 1 | $21 |
| Novartis | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,029 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $139,542 |
| JardianceEmpagliflozin | 77 | $104,980 |
| MyrbetriqMirabegron | 37 | $36,911 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $34,538 |
| OzempicSemaglutide | 30 | $31,235 |
| ProliaDenosumab | 17 | $30,134 |
| JanuviaSitagliptin Phosphate | 17 | $27,925 |
| XareltoRivaroxaban | 21 | $27,130 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $26,639 |
| EntrestoSacubitril/Valsartan | 14 | $24,280 |
| MounjaroTirzepatide | 21 | $20,336 |
| RoxicodoneOxycodone Hcl | 11 | $17,146 |
| Atorvastatin Calcium | 930 | $9,378 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $7,438 |
| Levothyroxine Sodium | 464 | $6,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $119 | $139,542123 claims |
| Boehringer IngelheimJardiance | $164 | $104,98077 claims |
| Astellas Pharma US IncMyrbetriq | $178 | $36,91137 claims |
| GSKTrelegy Ellipta | $227 | $34,53830 claims |
| Novo NordiskOzempic | $103 | $31,23530 claims |
| AmgenProlia | $587 | $30,13417 claims |
| MerckJanuvia | $171 | $27,92517 claims |
| Johnson & JohnsonXarelto | $320 | $27,13021 claims |
| NovartisEntresto | $16 | $24,28014 claims |
| Lilly USA, LLCMounjaro | $30 | $20,33621 claims |
| AstraZenecaSymbicort | $541 | $5,61114 claims |
| AbbVieSynthroid | $249 | $1,49738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Palm Springs
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.